Biocon Biologics receives Rs 555 crore Capital Injection from ADQ
Biocon Ltd has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment by Abu Dhabi based ADQ (ADQ), one of the region’s largest holding companies.
Biocon Ltd has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment by Abu Dhabi based ADQ (ADQ), one of the region's largest holding companies.
The company in a regulatory filing to the exchange, said, As per the terms of the proposed agreement, ADQ will invest Rs 555 Crore for a 1.80 per cent minority stake in the biosimilar business, valuing Biocon Biologics at a post-money valuation of ~USD 4.17 billion."
ADQ will invest Rs 555 crore for a 1.80 per cent minority stake in the biosimilar business, valuing Biocon Biologics at a post-money valuation of $4.17 billion.
The transaction is subject to customary condition precedents and approvals. Post the completion of this transaction, Biocon Ltd will hold 89.89 per cent stake in Biocon Biologics on a fully diluted basis.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said: "We welcome ADQ as our investment partner as we pursue our shared goal of expanding access to high-quality affordable biopharmaceuticals to patients across the globe. We are committed to pursue our affordable innovation model to generate savings for the healthcare systems worldwide. This investment is an endorsement of the value that Biocon Biologics business has built as a fully integrated pure-play biosimilars company and will enable us to expand our capabilities further. The current investment has put a post-money valuation of Biocon Biologics at USD 4.17 billion."
Dr Christiane Hamacher, CEO & Managing Director, Biocon Biologics, said: "The ADQ equity funding in Biocon Biologics endorses the value of our business model and strengthens our resolve to be the global leader in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming patients' lives. Our relentless desire to make a real difference pushes us to redefine innovation and build a disruptive business model that lowers treatment costs and improves healthcare outcomes, whilst delivering on shareholder value and our business objectives."
H.E. Mohamed Hassan Alsuwaidi, Chief Executive Officer of ADQ, said: "Our long-term ambition for ADQ's healthcare and pharma portfolio is to create a provision-centred, digitally enhanced ecosystem that is anchored in world-class clinical excellence, effective population health management and resilient supply chain infrastructure. While we anticipate this will unlock shareholder value, it will also, importantly, deliver positive socio-economic impact with better health outcomes, optimized healthcare spends and more opportunities for local and international talent. Biocon Biologic's proven R&D track record and partnerships worldwide provide us with an opportunity to benefit from the biosimilar sector that is set to grow as patents of originator biologics expire and patients demand lower-priced drugs globally."
Biocon Biologics is engaged in developing high-quality, affordable biosimilars that expand patient access to a cutting-edge class of therapies across the world. The company has one of the largest biosimilars portfolios globally, spanning recombinant human Insulin (rh-Insulin), insulin analogs, monoclonal antibodies and therapeutic proteins for oncology, immunology and other chronic disease areas. Biocon Biologics has the full spectrum of insulins (regular, basal and rapid) in its pipeline and the global scale necessary to make a difference to diabetes patients worldwide.
With the demand for biosimilars set to grow as patents of originator biologics expire and patients demand lower-priced drugs, Biocon Biologics is well-positioned to expand access.
Biocon Biologics had raised over USD 255 million from global marquee investors from January to November 2020. The Company has raised USD 75 million through a primary equity infusion by True North Fund for a 2.44 per cent stake; Tata Capital Growth Fund picked up a 0.85 per cent stake for USD 30 million. Goldman Sachs made a capital injection of USD 150 million in exchange for Optionally Convertible Debentures of Biocon Biologics.